Cybin (CYBN.NEO) to target alcoholism in upcoming CYB003 clinical studies Reza Golzadeh May 5, 2021 Agriculture, Mushrooms, News Summary, Psychedelics, Series Related Posts Top 5 stock gainers and losers: GOOD.V, GEN.V, NRX.V Top 5 stock gainers and losers: OOR.V, WEED.TO, CYBN.NE Cybin (CYBN.NEO) approved for first-in-human dosing MYND Life Sciences (MYND.C) provides unorthodox route to better mental health Psychedelics’ growing global map of legalization – another sector roundup From Leary’s lunacy to a legitimate lab – psychedelics sector in review More on CYBN.NE Top 5 stock gainers and losers: GOOD.V, GEN.V, NRX.V Vishal Toora February 9, 2024 Top 5 stock gainers and losers: OOR.V, WEED.TO, CYBN.NE Vishal Toora October 25, 2023 Cybin (CYBN.NEO) approved for first-in-human dosing Gaalen Engen February 1, 2023 MYND Life Sciences (MYND.C) provides unorthodox route to better mental health Joseph Morton January 12, 2022 Psychedelics’ growing global map of legalization – another sector roundup Gaalen Engen November 12, 2021 From Leary’s lunacy to a legitimate lab – psychedelics sector in review Gaalen Engen October 29, 2021 Load More Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Name * Email * Website Comment * Save my name, email, and website in this browser for the next time I comment.
MYND Life Sciences (MYND.C) provides unorthodox route to better mental health Joseph Morton January 12, 2022
Psychedelics’ growing global map of legalization – another sector roundup Gaalen Engen November 12, 2021
From Leary’s lunacy to a legitimate lab – psychedelics sector in review Gaalen Engen October 29, 2021